FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098483493> ?p ?o ?g. }

• W2098483493 endingPage "1862" @default.
• W2098483493 startingPage "1854" @default.
• W2098483493 abstract "The role of dietary components in cancer progression and metastasis is an emerging field of clinical importance. Many stages of cancer progression involve carbohydrate-mediated recognition processes. We therefore studied the effects of high pH- and temperature-modified citrus pectin (MCP), a nondigestible, water-soluble polysaccharide fiber derived from citrus fruit that specifically inhibits the carbohydrate-binding protein galectin-3, on tumor growth and metastasis in vivo and on galectin-3-mediated functions in vitro.In vivo tumor growth, angiogenesis, and metastasis were studied in athymic mice that had been fed with MCP in their drinking water and then injected orthotopically with human breast carcinoma cells (MDA-MB-435) into the mammary fat pad region or with human colon carcinoma cells (LSLiM6) into the cecum. Galectin-3-mediated functions during tumor angiogenesis in vitro were studied by assessing the effect of MCP on capillary tube formation by human umbilical vein endothelial cells (HUVECs) in Matrigel. The effects of MCP on galectin-3-induced HUVEC chemotaxis and on HUVEC binding to MDA-MB-435 cells in vitro were studied using Boyden chamber and labeling assays, respectively. The data were analyzed by two-sided Student's t test or Fisher's protected least-significant-difference test.Tumor growth, angiogenesis, and spontaneous metastasis in vivo were statistically significantly reduced in mice fed MCP. In vitro, MCP inhibited HUVEC morphogenesis (capillary tube formation) in a dose-dependent manner. In vitro, MCP inhibited the binding of galectin-3 to HUVECs: At concentrations of 0.1% and 0.25%, MCP inhibited the binding of galectin-3 (10 micro g/mL) to HUVECs by 72.1% (P =.038) and 95.8% (P =.025), respectively, and at a concentration of 0.25% it inhibited the binding of galectin-3 (1 micro g/mL) to HUVECs by 100% (P =.032). MCP blocked chemotaxis of HUVECs toward galectin-3 in a dose-dependent manner, reducing it by 68% at 0.005% (P<.001) and inhibiting it completely at 0.1% (P<.001). Finally, MCP also inhibited adhesion of MDA-MB-435 cells, which express galectin-3, to HUVECs in a dose-dependent manner.MCP, given orally, inhibits carbohydrate-mediated tumor growth, angiogenesis, and metastasis in vivo, presumably via its effects on galectin-3 function. These data stress the importance of dietary carbohydrate compounds as agents for the prevention and/or treatment of cancer." @default.
• W2098483493 created "2016-06-24" @default.
• W2098483493 creator A5008320327 @default.
• W2098483493 creator A5010903945 @default.
• W2098483493 creator A5019034726 @default.
• W2098483493 creator A5032550342 @default.
• W2098483493 creator A5038005961 @default.
• W2098483493 creator A5043613075 @default.
• W2098483493 creator A5055334649 @default.
• W2098483493 date "2002-12-18" @default.
• W2098483493 modified "2023-10-14" @default.
• W2098483493 title "Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin" @default.
• W2098483493 cites W1536370890 @default.
• W2098483493 cites W1638424324 @default.
• W2098483493 cites W1742680248 @default.
• W2098483493 cites W1893993890 @default.
• W2098483493 cites W1964314198 @default.
• W2098483493 cites W1971377557 @default.
• W2098483493 cites W1994360534 @default.
• W2098483493 cites W1994968541 @default.
• W2098483493 cites W2005063423 @default.
• W2098483493 cites W2009544696 @default.
• W2098483493 cites W2011467997 @default.
• W2098483493 cites W2019711017 @default.
• W2098483493 cites W2022130479 @default.
• W2098483493 cites W2045731370 @default.
• W2098483493 cites W2059591436 @default.
• W2098483493 cites W2063734246 @default.
• W2098483493 cites W2067791064 @default.
• W2098483493 cites W2090475723 @default.
• W2098483493 cites W2128495342 @default.
• W2098483493 cites W2134835093 @default.
• W2098483493 cites W2157172418 @default.
• W2098483493 cites W33416225 @default.
• W2098483493 cites W4254900727 @default.
• W2098483493 doi "https://doi.org/10.1093/jnci/94.24.1854" @default.
• W2098483493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12488479" @default.
• W2098483493 hasPublicationYear "2002" @default.
• W2098483493 type Work @default.
• W2098483493 sameAs 2098483493 @default.
• W2098483493 citedByCount "374" @default.
• W2098483493 countsByYear W20984834932012 @default.
• W2098483493 countsByYear W20984834932013 @default.
• W2098483493 countsByYear W20984834932014 @default.
• W2098483493 countsByYear W20984834932015 @default.
• W2098483493 countsByYear W20984834932016 @default.
• W2098483493 countsByYear W20984834932017 @default.
• W2098483493 countsByYear W20984834932018 @default.
• W2098483493 countsByYear W20984834932019 @default.
• W2098483493 countsByYear W20984834932020 @default.
• W2098483493 countsByYear W20984834932021 @default.
• W2098483493 countsByYear W20984834932022 @default.
• W2098483493 countsByYear W20984834932023 @default.
• W2098483493 crossrefType "journal-article" @default.
• W2098483493 hasAuthorship W2098483493A5008320327 @default.
• W2098483493 hasAuthorship W2098483493A5010903945 @default.
• W2098483493 hasAuthorship W2098483493A5019034726 @default.
• W2098483493 hasAuthorship W2098483493A5032550342 @default.
• W2098483493 hasAuthorship W2098483493A5038005961 @default.
• W2098483493 hasAuthorship W2098483493A5043613075 @default.
• W2098483493 hasAuthorship W2098483493A5055334649 @default.
• W2098483493 hasBestOaLocation W20984834931 @default.
• W2098483493 hasConcept C121608353 @default.
• W2098483493 hasConcept C126322002 @default.
• W2098483493 hasConcept C150903083 @default.
• W2098483493 hasConcept C185592680 @default.
• W2098483493 hasConcept C202751555 @default.
• W2098483493 hasConcept C203014093 @default.
• W2098483493 hasConcept C207001950 @default.
• W2098483493 hasConcept C2776336362 @default.
• W2098483493 hasConcept C2777411675 @default.
• W2098483493 hasConcept C2778608917 @default.
• W2098483493 hasConcept C2779013556 @default.
• W2098483493 hasConcept C2780394083 @default.
• W2098483493 hasConcept C502942594 @default.
• W2098483493 hasConcept C55493867 @default.
• W2098483493 hasConcept C71924100 @default.
• W2098483493 hasConcept C86803240 @default.
• W2098483493 hasConcept C96232424 @default.
• W2098483493 hasConceptScore W2098483493C121608353 @default.
• W2098483493 hasConceptScore W2098483493C126322002 @default.
• W2098483493 hasConceptScore W2098483493C150903083 @default.
• W2098483493 hasConceptScore W2098483493C185592680 @default.
• W2098483493 hasConceptScore W2098483493C202751555 @default.
• W2098483493 hasConceptScore W2098483493C203014093 @default.
• W2098483493 hasConceptScore W2098483493C207001950 @default.
• W2098483493 hasConceptScore W2098483493C2776336362 @default.
• W2098483493 hasConceptScore W2098483493C2777411675 @default.
• W2098483493 hasConceptScore W2098483493C2778608917 @default.
• W2098483493 hasConceptScore W2098483493C2779013556 @default.
• W2098483493 hasConceptScore W2098483493C2780394083 @default.
• W2098483493 hasConceptScore W2098483493C502942594 @default.
• W2098483493 hasConceptScore W2098483493C55493867 @default.
• W2098483493 hasConceptScore W2098483493C71924100 @default.
• W2098483493 hasConceptScore W2098483493C86803240 @default.
• W2098483493 hasConceptScore W2098483493C96232424 @default.
• W2098483493 hasIssue "24" @default.
• W2098483493 hasLocation W20984834931 @default.

• next